PET/MRI Imaging of Glutamate Release in the Brain

NCT02511691 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-08-12

No results posted yet for this study

Summary

Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.

Conditions

  • Healthy

Interventions

DRUG

18F-PSS232

Diagnostic PET Tracer

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Alfred Buck, Prof. Dr. · University of Zurich

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-03-03
Completion
2016-03-03

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511691 on ClinicalTrials.gov